文献速递核素与放射性配体治疗肿瘤 PET/CT放射性药物与辐射防护

[211At]YF2 在转移性去势抵抗性前列腺癌患者的首次人体评估

First-in-human evaluation of [211At]YF2 in patients with metastatic castration-resistant prostate cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-02-10

这项 Phase 0 微剂量研究在 3 例 PSMA 阳性转移性去势抵抗性前列腺癌(mCRPC)患者中评估了 PSMA 抑制剂 [211At]YF2 的生物分布与剂量学,利用 211At 衰变产生的 X 射线进行显像。结果显示 [211At]YF2 耐受良好(不良事件≤2 级),转移灶在 24 h 仍清晰显影,患者图像估算的肾脏剂量为 15.3 mGy/MBq,明显低于小鼠数据预测值。

要点

  • [211At]YF2 在 mCRPC 患者中给药安全,不良事件均≤2 级。
  • PSMA-PET 识别的转移灶在 24 h 仍见明显摄取,最显著病灶平均剂量 31.4 mGy/MBq。
  • 患者图像估算肾脏剂量 15.3 mGy/MBq,低于小鼠生物分布预测值。

核心结论

  • [211At]YF2 可安全用于 mCRPC 患者,211At 显像能清晰勾勒转移灶,正常器官蓄积带来有利剂量学,值得进一步临床开发。

研究设计与样本

  • Phase 0 微剂量首次人体研究,先在 CD-1 小鼠评估生物分布并用 Rapid 3D-RD 软件计算人体等效估算辐射剂量。
  • 3 例经 [68Ga]Ga-PSMA-11 PET/CT 确认 PSMA 阳性转移的 mCRPC 患者静脉注射 [211At]YF2(29.6-44.4 MBq)。
  • 于 1、4、24 h 行全身平面显像,4 和 24 h 行 SPECT/CT,并进行 7 d 安全性评估。
  • 手动勾画感兴趣区生成时间-放射性曲线,用 Rapid 3D-RD 软件计算辐射剂量学。

主要发现

  • 基于小鼠数据的初步人体剂量学估算显示肾脏受照剂量最高(35.14 mGy/MBq)。
  • [211At]YF2 耐受良好,所有不良事件均≤2 级。
  • [211At]YF2 初期在肾脏、膀胱、唾液腺和甲状腺高摄取,随后快速清除。
  • 24 h 时所有患者 PSMA-PET 识别的转移灶仍见明显 [211At]YF2 摄取,最显著转移灶平均剂量 31.4 mGy/MBq。
  • 由患者图像计算的肾脏剂量为 15.3 mGy/MBq,明显低于小鼠生物分布预测的人体剂量学。

临床怎么用

  • 本研究为 Phase 0 微剂量首次人体评估,支持 [211At]YF2 后续临床开发,尚不能直接指导常规临床用药决策。

局限性

  • 样本量仅 3 例患者,结果需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The prostate-specific membrane antigen (PSMA) inhibitor [211At]YF2 was investigated in a Phase 0 microdose study in patients with metastatic castration resistant prostate cancer (mCRPC). The x-rays from 211At decay were used to assess biodistribution and dosimetry. METHODS: The biodistribution of [211At]YF2 initially was evaluated in CD-1 mice and human-equivalent estimated radiation doses were calculated using Rapid 3D-RD software. Three patients with PSMA-positive metastases confirmed by [68Ga]Ga-PSMA-11 PET/CT received [211At]YF2 (29.6-44.4 MBq) intravenously. Whole-body planar imaging was performed at 1, 4, and 24 h while SPECT/CT was conducted at 4 and 24 h. Safety assessment was performed for 7 d. Volumes of interest were manually delineated to generate time-activity curves for radiation dosimetry calculation with Rapid 3D-RD software. RESULTS: Preliminary human dosimetry estimates based on murine data indicated that the kidneys received the highest dose (35.14 mGy/MBq). [211At]YF2 was well tolerated with all adverse events being ≤ Grade 2. High uptake of [211At]YF2 was observed initially in kidneys, bladder, salivary glands, and thyroid, followed by rapid clearance. Even at 24 h, pronounced uptake of [211At]YF2 in metastases identified by PSMA-PET was observed in all patients with the most prominent metastasis receiving an average dose of 31.4 mGy/MBq. A kidney dose of 15.3 mGy/MBq was calculated from patient images, considerably lower than predicted from murine biodistribution-derived human dosimetry. CONCLUSIONS: [211At]YF2 was safely administered to mCRPC patients and metastatic lesions were clearly delineated by 211At imaging. Normal organ accumulation resulted in favorable dosimetry. Based on these results, [211At]YF2 warrants further clinical development.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Wu X, Xiang Y, Zalutsky MR, et al. First-in-human evaluation of [211At]YF2 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2026. PMID: 41665675. doi:10.1007/s00259-025-07754-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。